Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449915 · ClinicalTrials.gov registry record · Phase 4
Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse
A Phase 4 study, sponsored by TriHealth.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT02449915 is a Phase 4 study that has completed, run by TriHealth. The registered enrollment target is 70 participants.
The verdict
NCT02449915, a Phase 4 study, has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
To determine if the injection of liposomal bupivacaine to laparoscopic port sites and rectocele repair incisions at the completion of a robotic sacrocolpopexy with concomitant rectocele repair will result in decreased postoperative pain compared to injection of placebo.
Interventions
- DRUG Placebo
- DRUG Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02449915
The ClinicalTrials.gov registry entry for NCT02449915 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02449915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02449915 about?
NCT02449915 is a clinical study titled "Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse". To determine if the injection of liposomal bupivacaine to laparoscopic port sites and rectocele repair incisions at the completion of a robotic sacrocolpopexy with concomitant rectocele repair will result in decreased postoperative pain compared to injection of placebo.
What is the current status of trial NCT02449915?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2015-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02449915?
The interventions under investigation include: Placebo (DRUG), Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT02449915?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.